Drugs / EXL01
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07128680 | Mar 2026 → Aug 2028 expected | clear cell renal carcinoma, sarcomatoid renal cell carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05542355 | Mar 2023 → Oct 2024 | Crohn disease | Exeliom Biosciences | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06448572 | Jul 2024 → Oct 2028 expected | non-small cell lung carcinoma | University Hospital, Lille | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06306014 | May 2024 → Jan 2028 expected | Clostridium difficile colitis | Hospices Civils de Lyon | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06925061 | Mar 2025 → Sep 2026 expected | Crohn disease | Madeleine Bezault | Recruiting | No outcome recorded |
| Phase 2 | NCT06551272 | Mar 2025 → Mar 2026 overdue | hepatocellular carcinoma | Center Eugene Marquis | Recruiting | No outcome recorded |
| Phase 2 | NCT06253611 | Apr 2024 → Sep 2027 expected | gastric cancer | GERCOR - Multidisciplinary Oncology Cooperative Group | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXL01 | “EXL01 is a live biotherapeutic product containing a strain of bacteria called Faecalibacterium prausnitzii.” NCT07128680 ↗ |
| Modality | Other / unclassified | “EXL01, a New Live Biotherapeutic Product” NCT06306014 ↗ |
| Route | Oral | “oral administration of EXL01” NCT05542355 ↗ |